Non-adherence to assigned treatment is a common issue in cluster randomised trials. In these settings, the efficacy estimand may also be of interest. Many methodological contributions in recent years have advocated using instrumental variables to identify and estimate the local average treatment effect. However, the clustered nature of randomisation in cluster randomised trials adds to the complexity of such analyses. In this paper, we show that the local average treatment effect can be estimated via two-stage least squares regression using cluster-level summaries of the outcome and treatment received under certain assumptions. We propose the use of baseline variables to adjust the cluster-level summaries before performing two-stage least squares in order to improve efficiency. Implementation needs to account for the reduced sample size, as well as the possible heteroscedasticity, to obtain valid inferences. Simulations are used to assess the performance of two-stage least squares of cluster-level summaries under cluster-level or individual-level nonadherence, with and without weighting and robust standard errors. The impact of adjusting for baseline covariates and of appropriate degrees of freedom correction for inference is also explored. The methods are then illustrated by reanalysing a cluster randomised trial carried out in a specific UK primary care setting. Two-stage least squares estimation using cluster-level summaries provides estimates with small to negligible bias and coverage close to nominal level, provided the appropriate small sample degrees of freedom correction and robust standard errors are used for inference.
Introduction
Cluster randomised trials (CRTs), which randomise groups of individuals, are common in public health and primary care. The adoption of this design is often justified given the reduction of 'cross-over contamination' between the experimental arms and improved adherence with allocated treatment. [1] [2] [3] Nevertheless, treatment non-adherence is as common in CRTs as it is in individually randomised trials. 4 Dealing with non-adherence is more challenging because there are at least two levels at which deviations from protocol can occur, e.g. cluster or individual level. 5 We say that adherence is at the cluster level if all individuals within a cluster receive the treatment the cluster was randomised to. In contrast, we say that adherence is at the individual level, if the treatment received varies across individuals within the same cluster, so that some individuals received the treatment allocated to their cluster, while others did not.
The standard analysis of randomised clinical trials is intention-to-treat (ITT), which compares average outcomes across randomised groups. However, if the effect of treatment received is confounded, in the sense that there are measured and unmeasured common causes of receiving treatment and experiencing the outcome, the ITT provides the causal effect of being offered, rather than of receiving the treatment. An ITT analysis with poor adherence may dilute a true treatment effect. 6 Recently, there has been an increased interest in estimating other estimands alongside the ITT, as highlighted by the International Council for Harmonisation addendum to guideline E9 (Statistical Principles for Clinical Trials). Amongst them, the causal effect in those adhering to treatment has been singled out as being of interest for patients. 7 In the presence of unmeasured confounding, instrumental variable (IV) methods can estimate consistently the causal effect of an exposure under certain assumptions. 8, 9 An IV is a variable which is correlated with the exposure but is not associated with any confounders of the exposure-outcome association, nor is there any pathway by which the IV affects the outcome, other than through the exposure.
Since randomised treatment is usually a valid instrument, IV methods have been proposed to estimate the treatment causal effect in the context of randomised clinical trials affected by non-adherence. 10, 11 The population to which an IV estimate applies, however, depends on the assumed behaviour of the instrument. 9 When, as it is often the case, randomised treatment influences treatment received monotonically, 9 in the sense that the level of treatment received is greater when randomised to treatment, than when randomised to the control (the precise technical definition will be given shortly), IV methods lead to estimating the causal effect among the adherers, known as the local average treatment effect (LATE) or complier-average causal effect.
This estimand can be estimated via the ratio estimator or the two-stage least squares (TSLS) approach. 12 The latter consists of a 'first stage', which regresses treatment received on randomised treatment, and a 'second stage', which models the outcome on the predicted treatment received. Additional covariates can be included in each stage to control for measured confounding or increase precision. The regression coefficient for the predicted treatment received in the second stage model is a consistent estimator of the LATE, provided that the first stage model is a linear regression, containing all the variables appearing in the second stage. 13, 14 Extensions of this approach for the estimation of LATE in CRTs have been proposed, ranging from a TSLS of individual-level data with variance inflation by the design effect factor 15 to multilevel mixture models that include the latent compliance class membership as a regressor and a random effect for cluster. 16, 17 An alternative approach suggested by Schochet 18 constructs Wald-type ratio estimators using cluster-level (CL) summaries for both treatment received and outcome.
In this paper, we focus on TSLS estimation applied to CL outcome summaries. Similar to Schochet, 18 this approach exploits well-known methods from CL analysis, which consist of calculating for each cluster a relevant summary measure of the individual-level outcomes, such as means or proportions, and then analysing these using appropriate statistical methods, such as regression. Because each cluster provides only one data point, the units of analysis can be considered to be independent, but the procedure is inefficient. 19 Estimation by weighted least squares, where the weights are defined either by the cluster size or by the so-called minimum variance weights, can improve the efficiency. 15 Comparing these alternative estimation strategies for the implementation of TSLS estimation using CL data is the focus of this paper. We also demonstrate that using individual-level covariateadjusted cluster summaries in the (weighted) TSLS regression can increase efficiency.
The rest of the paper proceeds as follows: 'Methodology' section provides an overview of CL analysis methods, defines the estimand of interest and the LATE and introduces the identification assumptions and the different CL TSLS approaches. The finite-sample performance of the methods considered is evaluated using Monte Carlo simulations, presented in 'LATE for CL data' section. In 'Simulation study' section, we illustrate the methods by re-analysing the TXT4FLUJAB trial, a UK-based CRT evaluating the effectiveness and efficacy of text messaging influenza vaccine reminders in increasing vaccine uptake amongst patients with chronic conditions. 20 We conclude with a 'Discussion' section.
Methodology
Consider a two-arm CRT, with n participants, indexed by i, in J clusters, indexed by j, each of size n j . Let Z j denotes the binary treatment randomly allocated at the CL with probability 0.50. Let Y ij denotes the continuous or binary outcome, and D ij 2 f0, 1g be the treatment received by individual i in cluster j. Let W j and X ij be baseline covariates at CL and individual level, respectively (which can be vectors of variables).
With a slight abuse of notation, we let Y j denote the CL outcome (mean or proportions), i.e. Y j ¼ 1 n j P n j i¼1 Y ij , hereafter referred to as the unadjusted CL (unCL) outcome. Analogously, let D j denotes the unCL treatment received, D j ¼ 1 n j P n j i¼1 D ij . In the CL adherence settings, D ij is constant within clusters, and therefore D j is binary. In contrast, when nonadherence is at the individual level, D j is a continuous measure that varies from 0 to 1, representing the proportion of individuals receiving the active treatment in cluster j.
CL analysis
The unCL analysis uses simple CL summary statistics as the outcomes in subsequent analyses. Let 2 denotes the variance of Y ij , which can be decomposed as 2 ¼ 2 þ 2 , where 2 is the between-cluster variance and 2 the within-cluster variance. The intra cluster correlation coefficient (ICC) for Y ij is then y ¼
where we have used the fact that y ¼ 2 = 2 in the last equality. 21 Since CL outcomes are continuous regardless of whether the original variable was binary, they can be thought to be approximately normally distributed provided n j is sufficiently large. Thus, a linear regression with CL outcome Y j as dependent variable and Z j as the explanatory variable can be fitted to estimate the ITT effects. In the simplest setting without adjustment for other covariates, we have
where j is a random error term, assumed to be independently and identically distributed (i.i.d.), with mean 0. The ITT is estimated by Z . Efficiency is gained by estimating this model using generalised least squares, with the weights being either the cluster size n j or the so-called minimum-variance weights given by 22
When y % 0, minimum-variance weights are approximately equivalent to cluster size weights, while if y % 1, minimum-variance weights are approximately 1. 21 These equivalences can have practical implications when the variance of j cannot be consistently estimated, for example if the number of clusters is small, so weighting by the cluster size or even no weights are viable alternatives. Where clusters are large, weighting by cluster size is inefficient. 23 Since the j can be heteroscedastic especially when cluster sizes are very imbalanced, the standard errors (SE) should be obtained using a method that takes this into account, such as the Huber-White SE 24 which are consistent when there is heteroscedasticity. 25 Finally, because each cluster now contributes only one observation, inference should be based on the number of clusters J. Therefore, if p is the number of parameters being estimated, hypothesis tests and confidence intervals (CIs) should be based on appropriate distributions, for example t JÀp and not on normal-based approximations. We refer to this as small-sample degrees of freedom (SSDF) correction. Where J is sufficiently large (>40), normal approximations are adequate.
Regression analyses of CL summary outcomes can only adjust for CL covariates directly, as using CL summaries for individual-level regressors is not appropriate. 15 However, where there is interest in adjusting for baseline covariates at the individual level, whether for scientific reasons or to increase statistical efficiency, this can be done through a two-step procedure. 26 First, an individual-level regression analysis of the outcome is performed incorporating all the relevant covariates into the regression model except for the treatment indicator and ignoring clustering, e.g. with only one covariate X ij , we have
In the second step, the sample mean of the fitted residuals for this modelê 1 ij is calculated for each cluster j
These are then used as CL outcomes in any subsequent analyses. See Appendix 1 for the formulation for binary outcomes.
We refer to these summaries as adCL outcomes. Regression models involving them can also be estimated by generalised least squares, with inference based on normal approximations or Huber-White SEs and/or SSDF corrections, as before. Of note, if CL covariates are used to compute adCL outcomes, the degrees of freedom must be further reduced by the number of CL regressors used to obtain the CL outcome. No such adjustment is necessary for individual-level variables. 26 In this work, we only use adCL outcomes obtained by adjusting for individual-level variables. In the remainder, we denote the CL summary outcomes by Y j , whether they are unCL or adCL, will be clear from the context.
LATE for CL data
Notation and technical assumptions Denote by Y ij ðd j Þ the potential outcome that would manifest if, possibly contrary to fact, the jth cluster to which the individual belongs receives treatment d j , a vector of length n j of 0s and 1s, where we are assuming no interference between clusters, i.e. the potential outcomes and potential treatment received of individuals in the jth cluster are unrelated to the treatment status of individuals in other clusters. 5 'No interference between clusters' is a special case of partial interference, where individuals can be partitioned into groups such that interference does not occur between individuals in different groups but may occur between individuals in the same group. 27 This is commonly assumed in clustered randomised trials. 16, 17 We also assume counterfactual consistency:
. . , n j and z and d.
The consistency assumption implies that the outcome realised under observation of treatment at level d will equal the potential outcome under a hypothetical intervention to set treatment to value d, regardless of the nature of this hypothetical intervention, in what is called 'treatment-variation irrelevance'. 28, 29 More precisely, if we index the different ways of setting the treatment at level d by k d , the consistency assumption says that
Estimand of interest and identification assumptions
Assuming no interference between clusters and consistency allows us to define the estimand of interest, the LATE. 8 In the setting considered here, where both Z j and D ij are binary, the vector of potential treatment received under alternative random allocation, ðD ij ð0Þ, D ij ð1ÞÞ partitions the participants into four different compliance classes: 30 
The estimand of interest here is the so-called population LATE, defined as
This is said to be a 'local' causal effect as it is conditional on the stratum of complier individuals. Following Schochet and Chiang, 5, 31 we write the cluster version of the corresponding identification assumptions 9 as follows:
A1. CL unconfoundedness: Z j ? ?D ij ðzÞ, Y ij ðz, D ij ðzÞÞ, z 2 f0, 1g: This is also known as cluster randomisation assumption and is often stated in terms of the cluster randomisation to treatment being independent of measured and unmeasured confounders of the relationship between the treatment-received and the outcome. In the context of cluster randomised trials, we know this holds by design.
A2. Exclusion restriction at the individual level: Conditional on the treatment received D ij ¼ d, the treatment assignment Z j has no effect on the outcome. In terms of potential outcomes, we have
A3. Instrument relevance: Also referred to as first stage assumption: Z j is causally associated with treatment received D ij , i.e. Z j 6? ?D ij .
We remark that in the standard TSLS literature, a weaker version of the assumption A3 is made instead, namely that the instrument Z and treatment received D are only associated, but not necessarily causally. Denote this assumption by A3'. In the causal inference literature, an 'associational' instrument is known as proxy or surrogate instrument. Now, if Z and D are associated but not causally associated, there exists a common cause V, which is the causal instrument, and may be unobserved. In order to define, identify and interpret the LATE causally, under A1, A2 and A3', we further require that Z is conditionally independent from D and Y given V and that V is binary. We refer the interested reader to Herna`n and Robins 32 for further details.
For point identification of local treatment effects, A4 monotonicity of the treatment mechanism is often assumed: D ij ð1Þ ! D ij ð0Þ. In the case of a causal binary instrument, as randomised treatment, the monotonicity asumption implies that there are no individuals who would have received the active treatment when randomised to control (Z ¼ 0) and not received it when randomised to it. This assumption is often referred informally to as 'there are no defiers'. 8 We remark that the definition and interpretation of the monotonicity assumption is also more complex in non-causal instrument settings. 33 The monotonicity assumption is often justified by design, when the active treatment is not available to those in the control group. Where this is not the case, the investigators have to argue carefully why monotonicity is still plausible.
We also remark that in the case of CL randomisation, but with individual-level non-adherence, we need to assume that monotonicity holds at the individual level. 31 For the CL non-adherence setting, where D ij does not vary within clusters, then this becomes monotonicity at the CL, i.e. D j (1) ¼ 1 and D j (0) ¼ 0.
An extra assumption necessary when using adCL is that the model used to derive them is correctly specified.
Cluster and individual-level non-adherence
The population-level LATE estimand can be thought of as a weighted average of the cluster-specific LATE j for each cluster j, namely
with n c,j is the number of individual-level compliers in each cluster j, assumed here to be >0 for all clusters. The weights corresponding to each j are j ¼ n c,j P J j¼1 n c,j , i.e. the number of cluster-specific compliers divided by the total number of compliers.
This result is useful when interpreting the estimates obtained using CL summaries. We first note that the Wald ratio estimand applied to CL summaries, CL , does not always correspond to the population LATE . The former can be expressed as 5
In the case where treatment received is at the CL (i.e. CL adherence), this CL Wald estimand indeed can be interpreted as the population LATE.
In the case where non-adherence varies at the individual level, it can be shown that CL ¼ P J j¼1 CL,j j where the CL-weights are CL,j ¼ n c,j =n j P j n c,j =n j , i.e. the normalised proportion of individual compliers in each cluster. 31 So, CL-LATE CL identifies the population LATE, equation (5) , only if (i) the cluster sizes n j are identical for all j or (ii) the cluster-specific LATEs j are the same across all clusters, i.e. j ¼ , for all j 2 f1, . . . , Jg.
In the remainder, with individual-level non-adherence, we assume that every cluster has the same cluster-specific LATE, but allow for the cluster sizes to vary. If this is not the case, the CL-LATE CL identifies a weighted average of the heterogeneous cluster-specific LATE because of clusters with the same proportions of compliers are weighted the same, without accounting for the cluster size.
TSLS for CL data
The conditional expectations appearing in the Wald estimand (equation (7)) can be estimated via standard TSLS regression of the CL summaries (referred to as CL-TSLS). CL-TSLS is most easily explained for settings without weights or covariate adjustment. The first stage fits a regression to CL treatment received D j on treatment assigned Z j . Then, in a second stage, a regression for the CL outcome on the predicted treatment received is fitted. This can use either unCL summaries or adCL summaries if there are baseline individual-level variables predictive of the outcome, as this can help gain efficiency. Crucially, both first and second stages must be linear models for the TSLS estimator to be guaranteed to be consistent. 14, 34 We have: , where we assume that CovðD, E½DjZÞ 6 ¼ 0.
Assuming that the residuals from the second stage ¼ Y À E½Y À IV D À E½DjZÞ are such that E½ 2 jZ ¼ z ¼ 2 Y , the asymptotic variance of the IV estimator simplifies to 2 ðD > P Z DÞ À1 , where P Z is the projection matrix CL covariates can be included in the regressions to increase precision. For example, with one CL covariate W j , we have
where the error terms are as before.
As with the CL estimation of ITT, where the number of clusters is small, the CIs are constructed using a t distribution with degrees of freedom equal to Jp, where p is the number of parameters estimated by the second stage (i.e. the SSDF correction). As before, minimum-variance or cluster size weights can be used to increase efficiency. Finally, the error terms in the CL-TSLS are assumed to be homoscedastic. Where this is not a sensible assumption, Huber-White SEs should be used. 35 
Simulation study
We now perform a simulation study comparing the finite sample performance of TSLS estimation applied to CL data. We simulate CRT individual-level data assuming that the control group does not have access to the active intervention, referred to as one-way non-compliance, at either CL or individual level. In this setting, there are only two compliance classes: compliers and never takers. With a fixed expected total sample size equal to 1000, we vary the number of clusters J and the average cluster size n j . The marginal ICC of Y also takes two values. The effect of individual and CL variables on the outcome and the treatment received also varies, so that the strength of the confounding is either low or high, while the value of the true LATE also has two levels. Table 1 summarises the factorial design and the values taken by the different levels.
More specifically, we simulate cluster randomised treatment Z j $ Bernð0:5Þ and two independent baseline covariates, a CL covariate W j $ Nð0, 2 W Þ and individual-level covariate X ij $ Nð0, 2 X Þ with a moderate ICC X ¼ 0:05 and with variance 2 W ¼ 2 X ¼ 0:08. We then generate a binary adherence class indicator variable C ij , which is considered as latent. Let C ij ¼ 1 for the compliers, 0 otherwise. For settings where adherence is at the CL, this is constant within clusters, under the following model
with W ¼ 0:05 equivalent to an odds ratio (OR) % 1:05 per unit increase in W (denoted 'small effect') and W ¼ 0:7 equivalent to OR % 2 ('large effect').
For settings with individual-level adherence, the data generating model is
We derive treatment received at the individual level as
so that those individuals in clusters randomly allocated to control have always control treatment, but those in clusters randomised to the active intervention can switch to the control treatment, depending on their adherence class. We finally generate continuous outcome Y ij , under the exclusion restriction assumption
with j $ Nð0, 2 Þ and ij $ Nð0, 2 Þ, where the values for 2 and 2 are chosen, such that the marginal ICC for Y has the corresponding value according to the simulated scenario, given that VarðY ij Þ ¼ 2 ¼ 1.
For simplicity, but without loss of generality, we assume that there is no direct effect of complying on the outcome, and thus C ¼ 0, so that the mean potential outcome in the control never-takers is equal to the mean potential outcome of the control compliers and thus complying with the control treatment has no effect on the outcome. Since CZ 6 ¼ 0, there is a non-zero effect of complying with the active arm (i.e. receiving active treatment). The choice of C does not affect our estimation, as the effect of C (and the intercept 0 ) cancels out for the average treatment effect in the compliers and non-compliers, respectively.
The choice of the parameters' values is reported in Table 1 . 
We need the data generating process to result in randomised treatment Z being a valid IV, but with this choice of parameters, some combinations may result in weak instruments, for example, CL non-adherence settings, with only five clusters per arm, and the proportion of non-adherent clusters set at 40% (the median proportion of non-adherent clusters reported in Agbla and DiazOrdaz 4 being 44.8%). Thus, after creating each dataset, we perform an unadjusted first stage regression of D j on Z j and reject simulated datasets where the resulting FÀstatistic is <10 (Staiger and Stock's rule of thumb for weak instruments 36 ). We continue this process until we have 2500 datasets per scenario.
Estimation in each scenario involves using unCL summary of treatment received in the first stage, and either unadjusted or individual-level variable adCL summary outcomes, for the second stage. Each regression in the TSLS was fitted via ordinary least squares or generalised least squares, the latter with either cluster size or minimum-variance weights. We also consider TSLS where each stage model is either unadjusted or adjusted for a CL variable. Finally, we obtain SEs assuming homoscedasticity or Huber-White SEs and SSDF-based or normal approximation CIs. A summary is given in Table 2 . Details of the Stata code used for analysis are found in the online Appendix.
The performance criteria used are empirical bias and coverage rates of the 95% CIs over the 2500 replicate datasets per scenario. For the bias, we construct a 95% CI using the Monte Carlo errors. The coverage rate sampling error, given the size of the simulation, results in a valid range between 94.1 and 95.9%. See Appendix 2 for the formal definitions.
Results
We present the results by plotting the empirical bias with the Monte Carlo error-based CIs. The coverage rate valid range is represented by horizontal-dashed lines. Figures 1 and 2 report the empirical bias and 95% CI coverage resulting from each of the different CL-TSLS estimators, when adherence is at CL or individual level, respectively, and for scenarios where the true LATE is large. The corresponding figures for small true LATE are shown in Appendix 4 (Figures 7 and 8) .
Each figure reports results where J ¼ 10 (Panel A, top) or J ¼ 50 (Panel B), and with the ICC for Y, Y is either small (first three columns) or large (last three columns). In each cell, the results for alternative combinations of TSLS (unadjusted/adjusted for W j ) applied to unCL or adCL outcomes are plotted along the horizontal axis. The different data generation scenarios are identified by Ã, þ , Â and , corresponding to varying strengths of the effects of X and W on Y.
We see that all CL-TSLS estimators show some finite sample bias in settings where the number of clusters is small (J ¼ 10, Panel A), regardless of whether the non-adherence was at the cluster or individual level and whether the CL summary for Y was adjusted or unadjusted or W j was included or not in the TSLS regressions. However, the Monte-Carlo error CIs includes 0 in many settings. The bias is more severe when the ICC for Y is larger (right hand side of each figure) . The bias is somewhat attenuated when we adjust for W j in the TSLS, and the nonadherence is at the CL (Figures 1 and 7) . In contrast, for settings with individual-level non-adherence, this adjustment instead increases the bias, especially if W has only a small confounding effect. In these scenarios, the estimates exhibit a small but statistically significant bias, which disappears when the number of clusters is larger (Figures 2 and 8) . In general, the bias is not affected by the choice of weighting strategy nor by whether Y is small or large. The bias is negligible for settings where the number of clusters is moderate or large (J ¼ 50).
Comparing the results of the second, third and fourth rows in each panel (Figures 1 and 2) , we see that the coverage rate is affected by the choice of SE estimation and also by whether SSDF correction is used. When the number of clusters is small, an SSDF correction must be used as failing to do so results in under-coverage (Panel A). The low coverage is more serious when TSLS adjusts for W (second and fourth set of results in each panel). Overall, the results in Panel A of each figure show that coverage is closer to the nominal levels when using SSDF correction when constructing CIs (third and fifth rows). Using Huber-White SE or not has little to no impact if there is no SSDF correction. However, the SSDF correction for the CIs resulting from a TSLS using unCL outcomes can lead to under-coverage, as shown in the specific case with CL non-adherence, large Y and large true LATE, but where only X is strongly associated with Y (Figures 1 and 7 , third and fifth rows of Panel A, righthand side columns, scenario represented by Â in the plots). The use of adCL outcomes (i.e. where the CL outcome is the residual after adjusting for individual-level variable X) recovers coverage to values close to nominal. This is not the case when the non-adherence is at the individual level, and both W and X are confounders in the data generating process.
In both cluster and individual-level non-adherence settings, it can be seen that using minimum-variance weights increases the coverage by a small fraction, when compared with cluster size weights, especially for scenarios with J ¼ 50 and large Y . However, since minimum-variance weights require an estimate of the CL variance, and this is badly estimated when the number of clusters is small (J ¼ 10), we can see that the minimum-variance weights are less efficient than using either no weights or cluster-size weights. This is most clearly seen when no Huber-White SE correction has been used.
We can also see that when SSDF correction is used, then not using Huber-White SE can result in small overcoverage especially for CL non-adherence settings, which is improved when Huber-White SE are used (Figures 1  and 7 , third and fifth rows of Panel A). When J ¼ 50 (Panel B), the use of SSDF-based distributions is not expected to make any material difference, and this is indeed the case. The impact of using Huber-White SE or the different weighting strategies is also minimal.
Additional simulations
Two extra additional scenarios are now considered to investigate the sensitivity of the CL-TSLS performance to number of clusters and cluster-size imbalances, at both CL and individual-level adherence, but focusing on settings where confounding is strong with a large true LATE.
In the first additional simulation, we explore the impact that the outcome ICC and the number of clusters have on bias, while leaving the expected total sample size fixed (¼ 1000).
We consider two marginal ICC for Y ij ( Y ¼ 0:05 and Y ¼ 0:80) and three average cluster sizes (n j ¼ 20, 10 and 2.5, corresponding to whether the number of clusters varied from J ¼ 50, 100 or 400), which includes one of the scenarios previously considered in the main simulations for comparison. Although CRTs rarely have ICCs above 0.10, 37 the value of Y ¼ 0:80 is included to evaluate the performance of the methods in extreme settings.
In the second additional set of simulations, we explore the effect of high cluster-size imbalances. While keeping the average sample size equal to 1000, and J ¼ 10 or 50, we create high cluster size imbalance using a Pareto distribution to generate the cluster sizes. 38 The Pareto distribution parameters are chosen so that approximately 40% of the clusters have a size below 15, and 60% a size above 15, while the average cluster size is 20 and the minimum cluster size is 10, resulting in approximately 1.8 for the shape and 9.1 for the scale. Figures 3 and 4 , corresponding to CL and individual-level non-adherence settings, show that for a fixed number of clusters (cells in the same row), the bias increases with increasing ICC for Y, but that as the number of clusters increases (moving down the column in the figure), CL-TSLS results in negligible mean bias, even a very large Y . It is well known that TSLS is only asymptotically unbiased, and with CL analyses, we expect the asymptotics to depend on the number of clusters and not the number of individuals. Nevertheless, the CL-summaries treated as outcomes for the two models involved in TSLS contain less 'information' when the ICC is higher, which translates into a larger number of clusters being necessary for the bias to be negligible.
Results
The impact of high cluster size imbalance is reported in Figures 5 and 6 , where non-adherence is at the CL and individual level, respectively. We see that even with the use of Huber-White SE, failure to do SSDF correction results in under-coverage, especially when Y is large. Looking at Panel B in Figure 6 , we can see that using clustersize weights results in even lower coverage. This is because cluster-size weights are known to perform well when the CL residuals are homoscedastic, which is unlikely when cluster sizes are very imbalanced. 15 The use of SSDF correction brings the coverage close to nominal levels.
Illustrative example
We now illustrate the methods in practice by applying each in turn to the analysis of the TXT4FLUJAB trial. This was a CRT of general practices (GP) in England aiming at estimating the effect of text messaging influenza vaccine reminders on increasing vaccine uptake in patients with chronic conditions, carried during the 2013 influenza season. 20 GPs were stratified by the type of software used for text messaging and randomised to either standard care (control group, 79 GPs and 51,136 patients) or a text messaging campaign (active group, 77 GPs and 51,121 patients). Practices were not blinded to their allocation. GPs were the unit of analysis, and the outcome of interest was the proportion of influenza vaccine uptake at the GP level.
Influenza vaccination within the GPs was automatically recorded in the clinical system from which the data were extracted, so there are no missing data.
Since non-adherence was anticipated, the original statistical analysis plan specified obtaining by IV regression an efficacy estimate at the GP level. 20 The original publication reported an estimated increase in vaccine uptake from texting reminders of 14.3% (95% CI: -0.59%-29.2%), 20 after dichotomising adherence at the CL as either 100% of eligible patients, compared with texting 5100%.
Adherence to the intervention at the individual level could not be measured for all practices because it was recorded in a usable form only for GPs using a specific software. Therefore, for these re-analyses, we restrict the dataset to 116 GPs (58 in the intervention and 58 in the standard care arm) for which individual-level adherence data are available. Six of the 58 practices (10%) in the intervention arm did not send any reminders. Conversely, 21 of the 58 practices (36%) in the standard care arm actually sent a reminder to at least one patient. Hence nonadherence is two-sided. It also varies at the individual level. The median (range) of percentage of non-adherence at the GP level was 0 (0-78.4%) and 21.0% (0-83.5%) in the control and active group, respectively (Table 3 ). The characteristics of the GPs and of the patients included in these analyses are comparable across trial groups (Table 3) ; further, the marginal ICC for individual-level outcome (vaccination) and treatment received (text message reminder) was 0.03 and 0.84 on the log-odds scale, respectively.
For our re-analysis, we begin by discussing the plausibility of the necessary assumptions. First, the consistency assumption in this setting implies that the means of sending and receiving the text message, as well as the timings are irrelevant, in the sense that all of these would lead to the same observed outcome. So whether the text was pre-programmed, or sent by a doctor or a nurse, or received in the morning or at night or weekend, it would have the same effect of either getting the patient to be vaccinated, or not, irrespective of any of these factors. This seems a reasonable assumption for this intervention.
In contrast, there is a small risk of interference. The cluster defined by GP practice should minimise this, as we only need to assume no interference at the CL, but it could be plausible that patients interact with those outside their GP, so that the exposure to a text message reminder of one patient may indeed affect the potential outcome, in this case, influenza vaccination of another patient from a different GP. The risk is small as usually close family members belong to the same GP. Now, regarding the identification assumptions, we note that the unconfoundedness of the CL randomised treatment assumption is satisfied by design. To check whether cluster randomisation is a relevant instrument, we perform a test on the first stage of the CL-TSLS. The corresponding F-statistic is Fð1, 114Þ ¼ 28:7 4 10, thus passing Staiger and Stock's rule of no null first-stage. 36 The exclusion restriction at the individual level implies that there is no other mechanism by which the GP being randomised to sending text vaccination reminders can affect a patient's actual vaccination uptake beside via the sending of the message. This assumption needs further justification, as in principle, a GP randomised to send reminders can be more conscious of the risks the patients face during the influenza season and use other means to Figure 6 . Extra simulation for very imbalanced cluster size settings. Bias (top row) and 95% CI coverage (Huber-White SEs (or not) and SSDF corrections (or not)) of the CL-LATE where non-adherence is at the individual-level, and a large true LATE. Estimates are obtained via unadjusted or adjusted TSLS with different weights (none, cluster size (CS), and minimum-variance (MV)). Small and large number of clusters results appears in Panels A and B, respectively. remind at-risk patients, either in person, by post or by putting out flyers and posters in the clinic. So, it is possible that there are patients who do not receive text reminders and yet are prompted to get vaccinated by other means, by virtue of their practice being in the active group. However, flyers, posters and postal letters already form part of regular care, so we believe they do not really vary by whether the GP is randomised to the active group.
Finally, the monotonicity assumption (that there are no defiers) also seems plausible as GPs randomised to the active group were more likely to send a text message reminder than those in the control group (see Table 3 ).
CL-TSLS on unCL outcomes was implemented adjusting and not adjusting for a baseline CL covariate, namely whether the clinic was open on the weekends (yes/no). Table 4 shows the CL-LATE estimates (expressed as mean risk differences), with 95% CIs and p-values obtained via different weighting strategies and corrections.
Using cluster-size weights results in different point estimates from the rest. This was expected as there is substantial cluster-size imbalance (cluster size range: 148-1678 in the control group and 79-3022 in the active group (Table 3) ). The results obtained using no weights or minimum-variance weights lead to point estimates that are very close to those found in the original publication. 20 Table 4 . LATE of text message reminders to receive flu vaccination on the uptake of flu vaccine in the TXT4FLUJAB trial, using unadjusted CL-summaries. Table 3 . Baseline characteristics and percentages of non-adherence for the TXT4FLUJAB trial.
Characteristics Control Active
In terms of inference, the use of SSDF correction in calculating CIs is not important, as the number of clusters is large, but the Huber-White SEs paired with minimum-variance weighting provides efficiency gains, especially for the adCL-TSLS analyses. Overall, however, the CIs are still very wide.
These results suggest that there is some evidence that receiving a text reminder increases the expected proportion of patients within a compliant practice that get vaccinated against influenza by 14% (95% CI: -0.5 to 29.3%, p ¼ 0.058, based on the adCL-TSLS using minimum-variance weights and normal-based CI with Huber-White SEs estimate).
Contrast this with the unCL-summaries mean risk difference ITT estimate, which indicates a 2.89% increase (95% CI: -0.17-5.95, p ¼ 0:064Þ, highlighting the dilution effects deriving from the non-adherence.
One of the disadvantages of TSLS is lack of efficiency. Adjusting for individual-level baseline covariates may help obtaining narrower CIs. Since CL-TSLS cannot adjust for individual-level covariates, we now perform the analyses using adCL summary outcomes, generated by adjusting for gender, age and the presence of disease. Results are reported in Table 6 in Appendix 3. The results do not materially change (weak evidence of a 13% increase vaccination uptake), possibly because these individual-level covariates are not strongly associated with the outcome.
The illustrative example shows the importance of choosing and pre-specifying the TSLS analysis according to the trial characteristics. In the example, the choice of weights changed the point estimate to such an extent that the small evidence in support of treatment benefit disappeared completely. So, if the trial has very imbalanced cluster sizes, Huber-White corrections can help for the SEs, but the point estimates may be biased, if large clusters are somewhat atypical.
Our application is limited by the availability of baseline CL variables. Since there was only one CL variable recorded, the impact of covariate adjustment on the CL-TSLS is negligible. Other limitations of these results include the possibility of measurement error, for if patients received their influenza vaccine outside the practice, this would not have been recorded in the system, unless the patient informed their GP.
Discussion
This paper demonstrates the use of TSLS regression applied to CL summaries (CL-TSLS) as a simple and valid method for obtaining estimates of the LATE in CRTs where non-adherence occurs at either the CL or the individual level. To improve the efficiency of CL-TSLS estimates, we proposed adjusting for baseline variables; if these are CL, in the TSLS regression, while if these are individual level, by adjusting the CL-summary outcomes before performing TSLS. The performance of CL-TSLS regression of either adjusted or unCL-outcomes and adjusting or not for CL-baseline variables was evaluated with different weighting strategies (none, cluster size, minimum variance) as well as the use of different methods for constructing CIs (alternatively using or not Huber-White SEs and/or SSDF correction) in a factorial simulation study.
We have demonstrated empirically through simulations that under the stated sufficient assumptions for identification, TSLS regression of CL summaries provides consistent estimates of the causal treatment effect in the sub-population of compliers, where non-adherence is at the CL. With individual-level non-adherence, the additional assumption that the cluster-specific LATE is the same across clusters is required for CL-TSLS to identify the population LATE. 31 Moreover, provided that an appropriate distribution with SSDF adjustment is used when the number of clusters is small and Huber-White SEs are used if there is high cluster size imbalance, valid 95% CIs can be constructed.
Our simulation study suggests that all weighting strategies perform similarly when the number of clusters is not small. When the number of clusters is small, minimum-variance weights tend to be badly estimated and are not recommended; furthermore when the cluster sizes are very variable, cluster-size weights should not be used. Although in the simulations, the choice of weights did not affect the point estimates, and these were affected in the illustrative example. Overall, our results show that, unless there are very few clusters, or the outcome ICC is large, minimum-variance weighting performs well. 23 An overall summary of these findings in the format of recommendations is given in Table 5 .
Although CL-TSLS is easy to implement, it suffers from being very inefficient. We can see this in the illustrative example where all CIs for the CL-TSLS LATE estimates are much wider than those for the estimated ITT. There are two reasons for this: CL analyses are inefficient, unless the cluster sizes are (almost) equal, 39 and TSLS is known to be inefficient, although adjusting for baseline covariates can ameliorate this. 14 In the context of CL analysis, it is only possible to include CL baseline covariates in the regressions. 15 However, we tested the performance of CL outcomes which are adjusted for individual-level covariates 26 and showed that this indeed has the potential to improve efficiency in certain settings.
For CL-TSLS analyses, inference should be based on the number of clusters, with CIs constructed by using tÀdistributions with degrees of freedom equal to Jp. 40 The outcome ICC value is important too, with higher ICCs requiring a larger number of clusters for the asymptotical arguments to work as well as whether the CL variances are homoscedastic. 15 Other methods for estimating causal treatment effects in CRTs with non-adherence at the individual level exist, in particular, Kang and Keele 31 have recently proposed a finite-sample estimator that identifies the population LATE and obtains valid inferences even when compliance is low.
We do not consider here situations where the identification assumptions are violated. There are several options to study the sensitivity to departures from these assumptions. For example, if the exclusion restriction does not hold, a Bayesian parametric model can use priors on the non-zero direct effect of randomisation on the outcome for identification. 41 Since the models are only weakly identified, the results depend strongly on prior distributions. Alternatively, violations of the exclusion restriction can also be handled by using baseline covariates to model the probability of compliance directly, within structural equation modelling via expectation-maximisation. 42, 43 We have only focused on LATE estimands. These are often criticised because the estimates obtained apply to the 'compliers' in the population, and these cannot be observed in practice, thus limiting applicability. However, LATE estimates may be used to provide information about the average causal effect in the entire population. 44 Moreover, the average treatment effect on the compliers is often of interest to patients and medical decision makers, especially when they expect patients to comply with the treatment. 45 Let M j andM j be the observed and predicted number of successes in the jth cluster, respectively. After fitting model (11) ,M j is calculated asM
Then the observed and predicted numbers of success are compared by computing a residual for each cluster. If we want to estimate the adjusted RD, the residual, known as difference-residual, for each cluster is calculated as e j ¼ ðM j ÀM j Þ=n j and treated as a continuous outcome in any subsequent analyses.
Appendix 2. Performance criteria
Let the mean of the estimated LATE across the replicate datasets in each scenario, indexed by l ¼ 1, . . . , , L, with L ¼ 2500 be
The following criteria were used to assess the performance of the methods investigated.
(a) Empirical bias: estimated by IV À CZ . 
